Joel Beatty

Work

Analyst Joel Beatty works at BAIRD and is focused on the Healthcare sector with 484 price targets and ratings documented since 2012 spanning on 40 stocks. Previously, Joel Beatty worked at CITI. Analyst's average stock valuation to be materialised ratio is 50.46% with an average time for price targets to be met of 159.37 days.

Most recent stock forecast was given on EDIT, Editas Medicine, Inc at 18-Nov-2022.

Joel Beatty best performing recommendations are on ARCT (ARCTURUS THERAPEUTICS HOLDINGS INC).
The best stock recommendation documented was for NVAX (NOVAVAX, INC) at 9/19/2016. The price target of $40 was fulfilled within 3 days with a profit of $10.2 (34.23%) receiving and performance score of 114.09.

Average potential price target upside

ALNY AMRN ARCT ARNA BPMC CBAY DBVT EIDX ESPR FGEN HALO IGMS IONS MDCO MDGL MIRM NGM NK NVAX PHAS PTCT SLDB SNDX SRPT VIR VNDA ARGX ARWR CATB CRDF EDIT ICPT NRIX BCEL TCON GERN KURA NERV AMAM XFOR
ALNY AMRN ARCT ARNA BPMC CBAY DBVT EIDX ESPR FGEN HALO IGMS IONS MDCO MDGL MIRM NGM NK NVAX PHAS PTCT SLDB SNDX SRPT VIR VNDA ARGX ARWR CATB CRDF EDIT ICPT NRIX BCEL TCON GERN KURA NERV AMAM XFOR